Annual Drug Patent Expirations for ONGLYZA
Onglyza is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for ONGLYZA.
This drug has one hundred and sixteen patent family members in forty-one countries.
The generic ingredient in ONGLYZA is saxagliptin hydrochloride. Two suppliers are listed for this compound. Additional details are available on the saxagliptin hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com